Results 161 to 170 of about 54,505 (255)

A Case of Systemic Lupus Erythematosus Initially Presenting With Generalized Lymphadenopathy: A Diagnostic Challenge. [PDF]

Cureus
Vázquez-Meraz E, Arellano-Galindo J, Díaz-Romero A, Pérez-Castro JA, Duarte-Salazar C.   +4 more
europepmc   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Beyond [¹⁷⁷Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents. [PDF]

BMC Cancer
Abdlkadir AS, Al-Adhami D, Moghrabi S, Sathekge MM, Kreissl M, Estrada-Lobato E, Shi H, Al-Ibraheem A.   +7 more
europepmc   +1 more source

Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Abstract Background Mood stabilizer augmentation is frequently used in treatment‐resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient. Case Presentation A 49‐year‐old Japanese woman with treatment‐resistant residual schizophrenia exhibited persistent
Yoshiki Kasagi, Naomichi Okamoto, Reiji Yoshimura   +2 more
wiley   +1 more source

In Regard to Huang et al. [PDF]

Adv Radiat Oncol
Sengul I, Sengul D.
europepmc   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang, Ngasin Lam, Xiaoming Huang, Yang Jiao   +3 more
wiley   +1 more source

Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reports. [PDF]

Ann Hematol
Muratore E, Giunchi V, Fusaroli M, Baccelli F, Gottardi F, Poluzzi E, Masetti R, Raschi E.   +7 more
europepmc   +1 more source

Successful in vitro propagation of feline coronavirus from clinically diagnosed feline infectious peritonitis cases using Vero cells: A potential model for future research

Veterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Feline coronavirus (FCoV) causes inapparent to progressive fatal feline infectious peritonitis (FIP) in domestic and wild cats, which affects multiple‐organ systems. Methods We investigated three clinically sick cats using different laboratory and molecular tests to diagnose and confirm FCoV and propagate the virus in Vero cell ...
Eaftekhar Ahmed Rana, Mahfuza Akther, Susan Beetson, Subir Sarker, Gabriele Rossi, Jasim M. Uddin   +5 more
wiley   +1 more source

Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series. [PDF]

Inflamm Bowel Dis
Hanna LN, Quraishi B, Pelly T, Lung P, Tozer P, Hart A, Wong SY, Powell N.   +7 more
europepmc   +1 more source